Abstract
ABSTRACT Objective: This study aimed to evaluate the concentration of ceruloplasmin (CP) in serum before and after Phase I periodontal therapy in patients with Stage II periodontitis. Materials and Methods: Forty subjects were divided into periodontally healthy subjects (n = 20) and Stage II periodontitis patients (n = 20). Serum CP levels were assessed and compared with clinical parameters (plaque index, gingival bleeding index, probing pocket depth, and clinical attachment level) before and after Phase-I therapy. Serum CP was measured using the immunoturbidometric method. Statistical analysis was conducted using SPSS version 20.0, with significance set at P ≤ 0.05. The independent t-test compared periodontally healthy and Stage II periodontitis patients. Results: Significant reductions were noted in all clinical parameters and serum CP levels. The baseline mean serum CP was 26.03 ± 4.371, decreasing to 22.85 ± 3.971 after 3 months of Phase I therapy. The mean difference in serum CP from baseline to 3 months was 3.185 ± 1.16 (P = 0.000). Conclusion: Periodontal inflammation may elevate serum CP levels and clinical parameter values in Stage II periodontitis patients. Phase I therapy effectively decreased serum CP levels and improved clinical parameters, suggesting its potential in managing periodontal disease.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call